Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

9591 results about "Erosion" patented technology

In earth science, erosion is the action of surface processes (such as water flow or wind) that removes soil, rock, or dissolved material from one location on the Earth's crust, and then transports it to another location (not to be confused with weathering which involves no movement). This natural process is caused by the dynamic activity of erosive agents, that is, water, ice (glaciers), snow, air (wind), plants, animals, and humans. In accordance with these agents, erosion is sometimes divided into water erosion, glacial erosion, snow erosion, wind (aeolic) erosion, zoogenic erosion, and anthropogenic erosion. The particulate breakdown of rock or soil into clastic sediment is referred to as physical or mechanical erosion; this contrasts with chemical erosion, where soil or rock material is removed from an area by its dissolving into a solvent (typically water), followed by the flow away of that solution. Eroded sediment or solutes may be transported just a few millimetres, or for thousands of kilometres.

Devices and methods for treating morbid obesity

InactiveUS20050177181A1Avoid tissue erosionRelieve stressSuture equipmentsStentsStomaMorbid obesity
The present invention provides devices and methods for attachment of an implanted device, such as an artificial stoma device, a gastrointestinal sleeve device or an attachment cuff, within a patient's digestive tract for treatment of obesity. Special surgical fasteners provide a lasting and durable attachment to the gastrointestinal tissue without causing excessive pressure that could result in tissue erosion and detachment of the implanted device. Fastener delivery devices that facilitate peroral placement and deployment of fasteners and secondary devices are also provided. Also described are implantable devices and attachment means that avoid causing excessive pressure within the tissue by having compliance that is compatible with the gastrointestinal tissues where it is attached.
Owner:VALENTX

Abuse-deterrent pharmaceutical compositions of opioids and other drugs

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Owner:COLLEGIUM PHARMA INC

Morphine controlled release system

InactiveUS20070003617A1Low administration frequencyAffecting extent of drug bioavailabilityBiocideNervous disorderMorphineDissolution
A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid-when tested in a Dissolution Test as described herein with or without application of sinkers-results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed pead concentration and a prolonged therapeutically effective plasma concentration upon oral administration. Once or twice daily administration is possible. The matrix typically comprises PEO and the active substance is typically an opioid such as morphine or a glucuronide thereof.
Owner:EGALET LTD

Acoustic nacelle inlet lip having composite construction and an integral electric ice protection heater disposed therein

An engine nacelle inlet lip includes both acoustic treatment and electric heating for ice protection. The inlet lip has a composite outer skin and a composite inner skin, with the composite outer skin having at least one integrated heater element embedded in the composite material. An acoustic cellular core positioned between the outer and inner skin acts to attenuate fan noise from the engine. Covering the outer skin and overlying the acoustic core is a perforated erosion shield having a first set of openings that pass entirely thorough its thickness. The composite outer skin includes a second set of openings such that sound waves can pass from an inner barrel portion of the inlet lip through the erosion shield, outer skin, and heater element to the underlying acoustic cellular core.
Owner:THE BF GOODRICH CO +1

Coatings for controlling erosion of a substrate of an implantable medical device

InactiveUS20050283229A1Reduce and inhibit and delay erosionReduce erosion rateStentsSurgeryInsertion stentMedical device
An implantable medical device, such as a stent, with a coating region for controlling erosion of the substrate region is disclosed.
Owner:ABBOTT CARDIOVASCULAR

Topography reduction and control by selective accelerator removal

Plating accelerator is applied selectively to a substantially-unfilled wide (e.g., low-aspect-ratio feature cavity. Then, plating of metal is conducted to fill the wide feature cavity and to form an embossed structure in which the height of a wide-feature metal protrusion over the metal-filled wide-feature cavity is higher than the height of metal over field regions. Most of the overburden metal is removed using non-contact techniques, such as chemical wet etching. Metal above the wide feature cavity protects the metal-filled wide-feature interconnect against dishing, and improved planarization techniques avoid erosion of the metal interconnect and dielectric insulating layer. In some embodiments, plating of metal onto a substrate is conducted to fill narrow (e.g., high-aspect-ratio feature cavities) in the dielectric layer before selective application of plating accelerator and filling of the wide feature cavity.
Owner:NOVELLUS SYSTEMS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products